AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05258890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Group Counseling
Description: Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
Study NCT05258890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Counseling
Description: The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
Study NCT04311996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
Study NCT04271436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
Study NCT04271436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] flurothymidine
Description: -Radiopharmaceutical
Study NCT06276881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Stimulation
Description: AI-guided visual stimuli presented on an electronic screen
Study NCT05564884 — intervention group
Intervention type: OTHER
Intervention: no intervantion
Description: no intervention
Study NCT06478797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid
Description: Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
Study NCT06478797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenalin
Description: Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
Study NCT05023616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time home CPR training
Description: The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
Study NCT05023616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CPR training
Description: Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance.
Study NCT05948670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISC-MVP
Description: DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
Study NCT05948670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DISC-CON
Description: DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
Study NCT05641428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARI-0001
Description: Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Study NCT05641428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axi-cel
Description: Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
Study NCT04311996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSST
Description: Participants will, via an online session, complete the TSST which is a standardized speech \& math performance known to elicit a cortisol stress response.
Study NCT05640479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
Study NCT05575167 — intervention group
Intervention type: DRUG
Intervention: Zoledronate or Alendronate
Description: infusion (for zoledronate) or oral digestion (for alendronate)
Study NCT05609045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized COVID-19 mRNA Vaccine
Description: RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
Study NCT05609045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 0.9% sodium chloride
Study NCT05640479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
Study NCT04528654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
Study NCT05402592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbonhydrate rich drink
Description: It will be prepared by adding 50 g of carbohydrates to 1200 ml of water in total and will be given to the patients the night before the surgery and the morning of the surgery.
Study NCT05402592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: A total of 1200 ml of water will be given to the patients the night before and the morning of the surgery.
Study NCT06049745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 Microgram Oral Tablet
Description: S.L misoprostol 400 mcg
Study NCT06120816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
Study NCT06244225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib； Sintilimab； HAIC
Description: Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: oral
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: oral
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: oral
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: oral
Study NCT06031454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: oral
Study NCT06293807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 2 % with 1:100,000 epinephrine
Description: Local anesthetic used during dental procedures
Study NCT06293807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5% with 1:200,000 epinephrine
Description: Local anesthetic used during dental procedures
Study NCT06293807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline solution used in place of local anesthetic
Study NCT05248945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
Study NCT05248945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
Study NCT06065033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance.
Study NCT05461677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAIRE smart walker
Description: Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
Study NCT05461677 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 4-wheeled walker
Description: Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
Study NCT06559163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRllb, resulting in down regulation of B cell activity.
Study NCT06559163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04801368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization of two local anesthetics.
Description: Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
Study NCT05461677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No walking aid
Description: Participants will walk along the 10-meter walkway 5 times without using a walking aid
Study NCT05871151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
Study NCT05871151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
Study NCT05871151 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
Study NCT06040099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)
Study NCT05778825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Minoxidil
Description: minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
Study NCT05778825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Minoxidil
Description: minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day
Study NCT05778825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for 4 months
Study NCT05749445 — intervention group
Intervention type: DRUG
Intervention: Nirmatrelvir-Ritonavir
Description: Nirmatrelvir-Ritonavir
Study NCT06257810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VIDAS® Dengue Antigen NS1, VIDAS® Anti-Dengue IgM, VIDAS® Anti-Dengue IgG, VIDAS® Anti-Chikungunya IgM and VIDAS® Anti-Chikungunya IgG
Description: For patients managed in an intervention site, a diagnostic test for dengue and chikungunya using VIDAS® as well as a screening test for malaria will be carried out. An awareness campaign on the use of VIDAS® diagnostic tests will be implemented as well.~The diagnosis will be based on the patient's clinical symptoms, the biological results of the VIDAS® tests for dengue and chikungunya, as well as the results of the tests for malaria.
Study NCT06257810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care practices
Description: For patients managed in a control site, the standard of care practices will be applied in the case of a febrile condition of undetermined etiology. This includes clinical diagnosis and, where appropriate, the use of routinely available diagnostic tests. At the end of the study, the collected samples will be tested using VIDAS® differential diagnosis tests to estimate the number of cases of dengue and chikungunya that have not been correctly diagnosed.
Study NCT06242249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-NK
Description: Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease.
Study NCT06399185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study NCT06399185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
Study NCT06399185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study NCT06399185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined dexmedetomidine-esketamine
Description: Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study NCT06575569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: Patients had no adverse events after 2 weeks of adaptive exercise training and voluntarily continued participants, intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times. Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and health education materials pushed by cardiovascular nurses.
Study NCT06575569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Using routine postoperative care and follow-up, establish WeChat group as contact for postoperative follow-up, no adverse events after 2 weeks of adaptive exercise training and voluntary participants, patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve). Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and pushed health education materials by cardiovascular nurses.
Study NCT06556238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Metabolite Ratio
Description: Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
Study NCT05153811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Study NCT05153811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Participants will engage with an application designed to gamify drinking reduction.
Study NCT05153811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
Study NCT06605976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DAX CoPilot Group
Description: Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
Study NCT05209451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital, evidence-based behavioral health program for smoking cessation
Description: Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.